DSDavid Stammers

David Stammers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David Stammers has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sulfhemoglobinemia associated with meconium ileus in cystic fibrosis

    by Chris Christensen, Gabilan Sivapatham, Martha L. McKinney, David Stammers


  • Open Access

    Enrolling children with acute lymphoblastic leukaemia on a clinical trial improves event-free survival: a population-based study

    by Caron Strahlendorf, Jason D Pole, Randy Barber, David Dix, Ketan Kulkarni, Emilie Martineau, Alicia Randall, David Stammers, Douglas Strother, Tony H Truong, et al.

    The objectives of this study were to describe the impact of trial enrollment at diagnosis on event-free and overall survival in paediatric acute lymphoblastic leukaemic (ALL) using a population-based approach. We conducted a retrospective cohort study that included children newly diagnosed with ALL between 1 and 14 years of age. The data source was the Cancer in Young People in Canada (CYP-C) national paediatric cancer population-based database. We conducted univariate and multiple Cox proportional hazards models. There were 2569 children with ALL; 1408 (54.8%) were enrolled on a clinical trial at initial diagnosis. Event-free survival at 5 years was 89.8%±0.9 vs 84.1%±1.2. (Pvs not enrolled (90.5%±1.0; P=0.001). In a model that adjusted for demographic, leukaemic and socioeconomic factors, enrollment on trials was significantly associated with better event-free survival (hazard ratio (HR) 0.67, 95% confidence interval (CI) 0.47–0.95; P=0.023), but not overall survival (HR 0.69, 95% CI 0.44–1.08; P=0.102). Event-free survival was significantly better in children with ALL enrolled on a clinical trial. Future research should identify barriers to clinical trial enrollment for children with ALL.


  • Open Access

    Most children with cancer are not enrolled on a clinical trial in Canada: a population-based study

    by Jason D. Pole, Randy Barber, Rose-Émilie Bergeron, Anne Sophie Carret, David Dix, Ketan Kulkarni, Emilie Martineau, Alicia Randall, David Stammers, Caron Strahlendorf, et al.

    Primary objective was to describe the proportion of children newly diagnosed with cancer enrolled on a therapeutic clinical trial. Secondary objectives were to describe reasons for non-enrollment and factors associated with enrollment on trials. In this retrospective cohort study, we included children newly diagnosed with cancer between 0 and 14 years of age and diagnosed from 2001 to 2012. We used data from the Cancer in Young People in Canada (CYP-C) national pediatric cancer population-based database. CYP-C captures all cases of pediatric cancer (0–14 years) diagnosed and treated at one of the 17 tertiary pediatric oncology centers in Canada. Non-enrollment was evaluated using univariate and multiple logistic regression analysis. There were 9204 children with cancer included, of whom 2533 (27.5%) were enrolled on a clinical trial. The most common reasons cited for non-enrollment were lack of an available trial (52.2%) and physician choice (11.2%). In multiple regression, Asian and Arab/west Asian race were associated with lower enrollment (P = 0.006 and P = 0.032 respectively). All cancer diagnoses were more likely to be enrolled compared to astrocytoma and children with acute lymphoblastic leukemia had an almost 18-fold increased odds of enrollment compared to astrocytoma (P < 0.0001). Greater distance from the tertiary care center was independently associated with non-enrollment (P < 0.0001). In Canada, 27.5% of children with cancer are enrolled onto therapeutic clinical trials and lack of an available trial is the most common reason contributing to non-enrollment. Future research should better understand reasons for lack of trial availability and physician preferences to not offer trials.


  • Evaluation of the need for chest X-rays in the management of asymptomatic, intraluminal vascular access device occlusion in childhood cancer

    by David Stammers, Bairbre Connolly, Leonardo R. Brandão, Sue Zupanec, Sumit Gupta

    Venous access device (VAD) occlusion from intraluminal thrombus is a common complication during childhood cancer treatment. Current practice at many institutions is to assess VAD position with a chest X-ray (CXR) prior to intraluminal administration of tissue plasminogen activator (tPA). We aimed to determine the utility of this practice. A retrospective chart review of children with newly diagnosed cancer with a VAD, treated at The Hospital for Sick Children between 2010 and 2011, was performed. Episodes of line occlusion were identified both by reviewing patient CXRs for indication and identifying tPA doses dispensed. These episodes were reviewed to determine whether CXR findings resulted in management other than tPA. Cases in which the X-ray resulted in a change in management were further reviewed to determine whether administration of tPA could have resulted in potential patient harm. A total of 330 patients with newly diagnosed cancer with VADs were identified. Eighty-five (25.8%) patients experienced 123 episodes of VAD occlusion. VAD occlusions occurred more frequently in patients with tunneled external central venous lines (16/39, 41.5%) and peripherally inserted central catheters (PICC) (27/73, 37.0%) versus PORT (42/216, 19.4%; P = 0.001). There were nine (8.1%) episodes of VAD occlusion evaluated with a CXR in which the findings led to a change in management other than administering tPA. In each case, multiple specialists independently concluded that administration of tPA would have been unlikely to cause patient harm. Routine CXRs prior to the administration of tPA for asymptomatic VAD occlusion can safely be omitted.


  • Cancer incidence, morbidity, and survival in Canadian first nation children: A Manitoba population-based study from the cancer in young people in Canada (CYP-C) registry

    by David M. Stammers, Sara J. Israels, Pascal J. Lambert, Geoff D.E. Cuvelier

    Background Health disparities between Canadian First Nation (FN) people and the rest of the national population exist. No studies have specifically documented cancer-related health outcomes in Canadian FN children. The purpose of this study was to describe the incidence of pediatric malignancies in Manitoba FN children, and to compare morbidity patterns and survival between FN and non-FN children with cancer in the Canadian province of Manitoba. Procedure A retrospective, population-based review of all children (0–14.99 years) diagnosed with malignancy (2001–2008) in Manitoba, Canada was undertaken using the Cancer in Young People in Canada registry. FN children were compared to the non-FN population for markers of morbidity and survival. Results The average annual age-standardized incidence rate for all childhood cancers in FN children was 132 per 1,000,000 per year. 240 children were included in the morbidity and survival analyses (38 FN; 202 non-FN). No differences were found between FN and non-FN children in time from first presentation of symptoms to consultation with an oncology specialist or diagnosis, or number of hospital admissions / total days of admission for treatment complications. Overall survival was inferior for FN children in univariable analysis (P = 0.048) but not when risk group was included in a multivariable analysis (P = 0.15). No difference in event free survival or cumulative incidence of relapse was identified. Conclusion The estimated incidence of childhood cancers in the Manitoba FN population is similar to provincial incidence rates. No differences in morbidity patterns or survival were found between Manitoba FN and non-FN children with cancer. Pediatr Blood Cancer 2014;61:2164–2169.


  • Open Access

    Case 2: Forehead mass in a teenager

    by David Stammers, Alaa Al Juaid, Sergio Fanella

    A 14-year-old boy with cerebral palsy and severe global developmental impairment secondary to congenital rubella infection presented to a community hospital with new-onset mid-frontal forehead swelling. There was no associated fever, irritability or decreased energy. He had a one-month history of purulent nasal discharge, for which he was started on oral clindamycin and an antihistamine. The swelling progressed despite six days of treatment, and he was subsequently transferred to a tertiary care centre for further investigation and management.